For patients with HR‐positive/HER2‐negative advanced breast cancer who previously underwent endocrine therapy, the SOLAR‐1 study assessed the efficacy and safety of combining fulvestrant with alpelisib versus fulvestrant and placebo. This evidence concerns the gene ERBB2 and breast cancer.